The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.

Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.

Melody Rasouli, MD, MBA, FACOG, explained why male fertility preservation information trails female content online and how cancer centers can fix it.

Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.

Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.

Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.

Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.

Melody Rasouli, MD, MBA, FACOG, discusses oncofertility gaps at NCI-designated cancer centers and ways to speed fertility referrals for patients.